var data={"title":"Pentamidine (systemic): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Pentamidine (systemic): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/785153?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=pentamidine-systemic-drug-information\" class=\"drug drug_general\">see &quot;Pentamidine (systemic): Drug information&quot;</a> and <a href=\"topic.htm?path=pentamidine-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Pentamidine (systemic): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44485848\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Pentam</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50021083\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Pentamidine Isetionate for Injection BP</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45043335\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antifungal Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antiprotozoal</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45043339\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=pentamidine-systemic-drug-information\" class=\"drug drug_general\">see &quot;Pentamidine (systemic): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Pneumocystis jirovecii</i> (PCP), prophylaxis (primary and secondary) in oncology patients (including HSCT recipients):</b> Limited data available: <b>Note:</b> For patients intolerant to sulfamethoxazole and trimethoprim. Children &ge;2 years and Adolescents: IV: 4 mg/kg/dose once a month (Kim 2008; Prasad 2007); in HSCT recipient doses have been administered every 2 to 4 weeks (Tomblyn [CDC/IDSA 2009]) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>PCP, treatment (moderate-severe disease): Note:</b> For patients who cannot tolerate or who fail to respond to 5 to 7 days of sulfamethoxazole and trimethoprim.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling: Infants &ge;5 months, Children, and Adolescents: IM, IV: 4 mg/kg/dose once daily for 14 to 21 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">HIV-exposed/-positive: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children: IV: 4 mg/kg/dose once daily; if clinical improvement after 7 to 10 days of therapy, may change to an oral regimen to complete a 21-day course (DHHS [pediatric] 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents: IV: 4 mg/kg/dose once daily for 21 days; some experts recommend a dose reduction to 3 mg/kg/dose for toxicity (DHHS [adult] 2015) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Non-HIV-exposed/-positive: Infants, Children, and Adolescents: IV: 3 to 4 mg/kg/dose once daily for 21 days (Bradley 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Trypanosomiasis; treatment (non-CNS disease):</b> Infants, Children, and Adolescents:  IM, IV: 4 mg/kg/dose once daily for 7 to 10 days (Bradley 2015; <i>Red Book</i> (AAP) 2015) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>PCP, treatment (moderate-severe disease):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer's labeling: IM, IV: 4 mg/kg/dose once daily for 14 to 21 days </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">AIDS<i>Info</i> guidelines (HIV-infected/-exposed): IV: 4 mg/kg/dose once daily for 21 days; some experts recommend a dose reduction to 3 mg/kg/dose for toxicity (DHHS [adult] 2015) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">\n      <b>Dosage adjustment in renal impairment:</b> The FDA-approved labeling recommends that caution should be used in patients with renal impairment; however, no specific dosage adjustment guidelines are provided. The following guidelines have been used by some clinicians (Aronoff 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Infants, Children, and Adolescents: IV: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">GFR &gt;30 mL/minute/1.73 m<sup>2</sup>: No adjustment required </p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">GFR 10 to 30 mL/minute/1.73 m<sup>2</sup>: Administer 4 mg/kg/dose every 36 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup> and peritoneal dialysis: Administer 4 mg/kg/dose every 48 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">Hemodialysis: Administer 4 mg/kg/dose every 48 hours, after dialysis on dialysis days </p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">Peritoneal dialysis: 4 mg/kg/dose every 48 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">Continuous renal replacement therapy: No adjustment required </p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Adults: IV: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">CrCl &ge;10 mL/minute: No adjustment required </p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">CrCl &lt;10 mL/minute: Administer 4 mg/kg/dose every 24 to 36 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">Hemodialysis: Administer 4 mg/kg/dose every 48 hours and 750 mg after each dialysis </p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">Peritoneal dialysis: 4 mg/kg/dose every 48 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">Continuous renal replacement therapy: No adjustment required </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustment provided in themanufacturer's labeling; has not been studied. Use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44485901\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection, as isethionate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pentam: 300 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44485850\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45043341\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM: Administer deep IM </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Administer by slow IV infusion over a period of at least 60 to 120 minutes; rapid IV administration can cause severe hypotension </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Irritant with vesicant-like properties; ensure proper needle or catheter placement prior to and during infusion. Avoid extravasation. If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do NOT flush the line); remove needle/cannula; elevate extremity. Apply dry warm compresses (Reynolds 2014). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44485867\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store intact vials at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); protect from light. Do not use sodium chloride for initial reconstitution (sodium chloride will cause precipitation).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Reconstituted solution is stable for 48 hours in the vial at room temperature and protected from light. Solutions for injection (1 to 2.5 mg/mL) in D<sub>5</sub>W are stable for at least 24 hours at room temperature. Store at room temperature to avoid crystallization. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45043336\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Parenteral: Treatment of pneumonia caused by <i>Pneumocystis jirovecii</i> (formerly <i>carinii</i>) (PCP) (FDA approved in ages &gt;4 months and adults). <b>Note:</b> The CDC recommends pentamidine for patients who cannot tolerate or who fail to respond to sulfamethoxazole and trimethoprim; has also been used in the treatment of African trypanosomiasis. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44486431\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Hypotension</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Confusion, hallucinations</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Skin rash </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Hypoglycemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Anorexia, dysgeusia, nausea </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Anemia, leukopenia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Increased liver enzymes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Local: Injection site reaction (intramuscular; includes sterile abscess, necrosis, pain, induration) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Renal: Azotemia, increased blood urea nitrogen, increased serum creatinine, renal insufficiency</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Rare but important or life-threatening: Abdominal pain, acute pancreatitis, acute rhinitis, ageusia, amnesia, anosmia, anxiety, arthralgia, blepharitis, blurred vision, bronchitis, cardiac arrhythmia, cerebrovascular accident, chest congestion, chest tightness, chills, confusion, conjunctivitis, cyanosis, depression, dermatitis, desquamation, diabetes mellitus, diabetic ketoacidosis, diarrhea, disseminated intravascular coagulation, dizziness, drowsiness, dry hair, dyspepsia, dyspnea, emotional lability, eosinophilia, eosinophilic pneumonitis, erythema, extrapulmonary pneumocystosis, extravasation (tissue ulceration, necrosis, and/or sloughing), eye pain, flank pain, gag reflex, hair breakage, headache, hearing loss, hematochezia, hematuria, hemoptysis, hepatic insufficiency, hepatitis, hepatomegaly, hyperglycemia, hyperkalemia, hypersensitivity reaction, hypertension, hyperventilation, hypocalcemia, hypoesthesia, hypomagnesemia, insomnia, interstitial pneumonitis, laryngitis, laryngospasm, melena, nasal congestion, nephritis, nervousness, neuralgia, neuropathy, neutropenia, night sweats, palpitations, pancreatitis, pancytopenia, paranoia, paresthesia, peripheral neuropathy, phlebitis, pleurisy, pneumothorax, prolonged prothrombin time, pruritus, pulmonary disease, rales, renal failure, renal insufficiency, seizure, serious infection (extrapulmonary pneumocystosis), sialorrhea, splenomegaly, Stevens-Johnson syndrome, ST segment changes on ECG, syncope, tachycardia, tachypnea, torsades de pointes, tremor, unsteady gait, urinary incontinence, vasodilation, vasculitis, ventricular tachycardia, vertigo, vomiting, xeroderma, xerostomia </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44485863\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to pentamidine isethionate or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44485864\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypotension: Severe hypotension (some fatalities) has been observed, even after a single dose. May occur with either IV or IM administration, although more common with rapid IV administration. Monitor blood pressure during (and after) infusion.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; QT prolongation: May cause QT prolongation and subsequent torsade de pointes; avoid use in patients with diagnosed or suspected congenital long QT syndrome.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Stevens-Johnson syndrome: Has been reported with use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiovascular disease: Use with caution in patients with preexisting cardiovascular disease; hyper-/hypotension and arrhythmia, including ventricular tachycardia (eg, torsade de pointes) have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Diabetes: Use with caution in patients with diabetes mellitus; hyper-/hypoglycemia and pancreatic islet cell necrosis with hyperinsulinemia has been reported. Symptoms may occur months after therapy; monitor blood glucose daily on therapy and periodically thereafter.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extravasation: Intravenous pentamidine is an irritant with vesicant-like properties. Ensure proper needle or catheter placement prior to and during infusion; avoid extravasation. Ulceration, tissue necrosis, and/or sloughing have been reported with extravasation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hematologic disorders: Use with caution in patients with current evidence and/or prior history of hematologic disorders; anemia, leukopenia and/or thrombocytopenia have been reported. Concurrent use with other bone marrow suppressants may increase the risk for myelotoxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypocalcemia: Use with caution in patients with hypocalcemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pancreatitis: Use with caution in patients with a history of pancreatic disease or elevated amylase/lipase levels; acute pancreatitis (with fatality) has been reported. Discontinue pentamidine if signs/symptoms of acute pancreatitis occur. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drugs with QT prolongation potential: Avoid concurrent use with other drugs known to prolong QTc interval.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Nephrotoxic drugs: Concurrent use with other nephrotoxic drugs may increase the risk for nephrotoxicity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44486436\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44486433\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=104536&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Androgens: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<b> Exceptions: </b>Danazol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Foscarnet: Pentamidine (Systemic) may enhance the adverse/toxic effect of Foscarnet. The specific toxicities may include hypocalcemia, renal failure, and QT-prolongation.  Management: Consider alternatives to this combination when possible.  If this combination must be used, monitor patients more closely for hypocalcemia, renal dysfunction, and QT interval prolongation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hydroxychloroquine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypoglycemia-Associated Agents: May enhance the hypoglycemic effect of other Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mequitazine: Pentamidine (Systemic) may enhance the arrhythmogenic effect of Mequitazine.  Management: Consider alternatives to pentamidine or mequitazine when possible.  While this combination is not specifically contraindicated, mequitazine labeling describes this combination as discouraged.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pegvisomant: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probucol: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prothionamide: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): May enhance the QTc-prolonging effect of other QTc-Prolonging Agents (Moderate Risk). Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Quinolones may diminish the therapeutic effect of Blood Glucose Lowering Agents. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Xipamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44485859\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44485860\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies were not conducted by the manufacturer. Pentamidine crosses the human placenta (Fortunato 1989; Schwebke 1995).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Intravenous pentamidine can be used as an alternative treatment in pregnant females with HIV infection for mild to moderate <i>Pneumocystis jirovecii</i> pneumonia (HHS [OI; adult] 2017). Pentamidine may be used to treat stage one trypanosomiasis caused by <i>T. brucei gambiense </i>(CDC 2016); information related to treatment of pregnant females for this indication is limited (Pohlig 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45043342\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Liver function tests, renal function tests (daily), blood glucose (daily), serum potassium and calcium, CBC with differential and platelet count, ECG, blood pressure </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44485871\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Interferes with microbial RNA/DNA, phospholipids and protein synthesis, through inhibition of oxidative phosphorylation and/or interference with incorporation of nucleotides and nucleic acids into RNA and DNA</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44485873\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: IM: Well absorbed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>dss</sub>: Binds to tissues and plasma protein; high concentrations are found in the liver, kidney, adrenals, spleen, lungs, and pancreas; poor penetration into CNS; IV: 821 &plusmn; 535 L; IM: 2724 &plusmn; 1066 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: IV: 5 to 8 hours; IM: 7 to11 hours; may be prolonged with severe renal impairment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (IV: &le;12% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44485903\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Pentam Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (1): $200.27</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45524660\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Manicare (AR);</li>\n      <li>Pentacarinat (BE, BR, CH, CZ, DE, ES, FR, HK, NZ, SE, TH);</li>\n      <li>Pentam (GR);</li>\n      <li>Pentamina (AU)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 73, 160.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Nelson JD, Kimberlin DK, et al, eds. <i>Nelson's Pediatric Antimicrobial Therapy</i>. 21th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention, &ldquo;Trypanosomiasis.&rdquo;  <a href=\"http://www.cdc.gov/parasites/sleepingsickness/health_professionals/index.html#tx\" target=\"_blank\">http://www.cdc.gov/parasites/sleepingsickness/health_professionals/index.html#tx</a>. Updated 2013. Accessed July 7, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Comtois R, Pouliot J, Gervais S, et al, &ldquo;High Pentamidine Levels Associated With Hypoglycemia and Azotemia in a Patient With <i>Pneumocystis carinii</i> Pneumonia,&rdquo; <i>Diagn Microbiol Infect Dis</i>, 1992, 15(6):523-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentamidine-systemic-pediatric-drug-information/abstract-text/1424505/pubmed\" target=\"_blank\" id=\"1424505\">1424505</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Conover B, Goldsmith JC, Buehler BA, et al, &quot;Aerosolized Pentamidine and Pregnancy,&quot; <i>Ann Intern Med</i>, 1988, 109(11):927.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentamidine-systemic-pediatric-drug-information/abstract-text/3190049/pubmed\" target=\"_blank\" id=\"3190049\">3190049</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Conte JE Jr, &ldquo;Pharmacokinetics of Intravenous Pentamidine in Patients With Normal Renal Function or Receiving Hemodialysis,&rdquo; <i>J Infect Dis</i>, 1991, 163(1):169-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentamidine-systemic-pediatric-drug-information/abstract-text/1984463/pubmed\" target=\"_blank\" id=\"1984463\">1984463</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cortese LM, Gasser RA, Jr, Bjornson DC, et al, &ldquo;Prolonged Recurrence of Pentamidine-Induced Torsade de Pointes,&rdquo; <i>Ann Pharmacother</i>, 1992, 26(11):1365-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentamidine-systemic-pediatric-drug-information/abstract-text/1477438/pubmed\" target=\"_blank\" id=\"1477438\">1477438</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Department of Health and Human Services. November 2013. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel  on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. 2015. Available at <a href=\"https://aidsinfo.nih.gov/contentfiles/lvguidelines/Adult_OI.pdf\" target=\"_blank\">https://aidsinfo.nih.gov/contentfiles/lvguidelines/Adult_OI.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fortunato SJ and Bawdon RE, &quot;Determination of Pentamidine Transfer in the <i>in vitro</i> Perfused Human Cotyledon With High-Performance Liquid Chromatography,&quot; <i>Am J Obstet Gynecol</i>, 1989, 160(3):759-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentamidine-systemic-pediatric-drug-information/abstract-text/2929699/pubmed\" target=\"_blank\" id=\"2929699\">2929699</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gates HS Jr and Barker CD, &quot;<i>Pneumocystis carinii</i> Pneumonia in Pregnancy. A Case Report,&quot; <i>J Reprod Med</i>, 1993, 38(6):483-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentamidine-systemic-pediatric-drug-information/abstract-text/8331631/pubmed\" target=\"_blank\" id=\"8331631\">8331631</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goa KL and Campoli-Richards DM, &ldquo;Pentamidine Isethionate. A Review of Its Antiprotozoal Activity, Pharmacokinetic Properties and Therapeutic Use in <i>Pneumocystis carinii</i> Pneumonia,&rdquo; <i>Drugs</i>, 1987, 33(3):242-58.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Department of Health and Human Services. November 2013. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. September 2015. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed October 8, 2015</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S and Koren G, &ldquo;Estimation of Fetal Risk From Aerosolized Pentamidine in Pregnant Healthcare Workers,&rdquo; <i>Chest</i>, 1994, 106(5):1460-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentamidine-systemic-pediatric-drug-information/abstract-text/7956402/pubmed\" target=\"_blank\" id=\"7956402\">7956402</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kim SY, Dabb AA, Glenn DJ, et al, &ldquo;Intravenous Pentamidine is Effective as Second Line Pneumocystis Pneumonia Prophylaxis in Pediatric Oncology Patients,&rdquo; <i>Pediatr Blood Cancer</i>, 2008, 50(4):779-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentamidine-systemic-pediatric-drug-information/abstract-text/17635000/pubmed\" target=\"_blank\" id=\"17635000\">17635000</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nanda D, Tannenbaum I, Landesman S, et al, &quot;Pentamidine Prophylaxis in Pregnancy,&quot; <i>Am J Obstet Gynecol</i>, 1992, 166:387.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pelucio MT, Rothenhaus T, Smith M, et al, &ldquo;Fatal Pancreatitis as a Complication of Therapy for HIV Infection,&rdquo; <i>J Emerg Med</i>, 1995, 13(5):633-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentamidine-systemic-pediatric-drug-information/abstract-text/8530781/pubmed\" target=\"_blank\" id=\"8530781\">8530781</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pentam prescribing information, American Pharmaceutical Partners Inc, Schaumburg, IL, December 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pohlig G, Bernhard SC, Blum J, et al. Efficacy and Safety of Pafuramidine versus Pentamidine Maleate for Treatment of First Stage Sleeping Sickness in a Randomized, Comparator-Controlled, International Phase 3 Clinical Trial.<i> PLoS Negl Trop Dis</i>. 2016;10(2):e0004363.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentamidine-systemic-pediatric-drug-information/abstract-text/26882015/pubmed\" target=\"_blank\" id=\"26882015\">26882015</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prasad P, Nania JJ, and Shankar SM, &ldquo;Pneumocystis Pneumonia in Children Receiving Chemotherapy,&rdquo; <i>Pediatr Blood Cancer</i>, 2008, 50(4):896-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentamidine-systemic-pediatric-drug-information/abstract-text/17458875/pubmed\" target=\"_blank\" id=\"17458875\">17458875</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reynolds PM, Maclaren R, Mueller SW, Fish DN, Kiser TH. Management of Extravasation Injuries: A Focused Evaluation of Noncytotoxic Medications [published online ahead of print January 13, 2014]. <i>Pharmacotherapy</i>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentamidine-systemic-pediatric-drug-information/abstract-text/24420913/pubmed\" target=\"_blank\" id=\"24420913\">24420913</a>]</span><span class=\"doi\">10.1002/phar.1396</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schwebke K, Fletcher CV, Acosta EP, et al, &quot;Pentamidine Concentrations in a Mother With AIDS and in Her Neonate,&quot; <i>Clin Infect Dis</i>, 1995, 20(6):1569-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentamidine-systemic-pediatric-drug-information/abstract-text/7548518/pubmed\" target=\"_blank\" id=\"7548518\">7548518</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smaldone GC, Vinciguerra C, and Marchese J, &quot;Detection of Inhaled Pentamidine in Health Care Workers,&quot; <i>N Engl J Med</i>, 1991, 325(12):891-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentamidine-systemic-pediatric-drug-information/abstract-text/1875979/pubmed\" target=\"_blank\" id=\"1875979\">1875979</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sperling RS, Stratton P, O'Sullivan MJ, et al, &quot;A Survey of Zidovudine Use in Pregnant Women With Human Immunodeficiency Virus Infection,&quot; <i>N Engl J Med</i>, 1992, 326(13):857-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentamidine-systemic-pediatric-drug-information/abstract-text/1542322 /pubmed\" target=\"_blank\" id=\"1542322 \">1542322 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tomblyn M, Chiller T, Einsele H, et al, &ldquo;Guidelines for Preventing Infectious Complications Among Hematopoietic Cell Transplantation Recipients: A Global Perspective,&rdquo; <i>Biol Blood Marrow Transplant</i>, 2009, 15(10):1143-238.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentamidine-systemic-pediatric-drug-information/abstract-text/19747629/pubmed\" target=\"_blank\" id=\"19747629\">19747629</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 104536 Version 34.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F44485848\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F50021083\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F45043335\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F45043339\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F44485901\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F44485850\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F45043341\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F44485867\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F45043336\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F44486431\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F44485863\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F44485864\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F44486436\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F44486433\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F44485859\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F44485860\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F45043342\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F44485871\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F44485873\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F44485903\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F45524660\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/104536|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=pentamidine-systemic-drug-information\" class=\"drug drug_general\">Pentamidine (systemic): Drug information</a></li><li><a href=\"topic.htm?path=pentamidine-systemic-patient-drug-information\" class=\"drug drug_patient\">Pentamidine (systemic): Patient drug information</a></li></ul></div></div>","javascript":null}